By a News Reporter-Staff News Editor at Blood Weekly -- Fresh data on Blood Research are presented in a new report. According to news reporting originating in Seattle, Washington, by NewsRx journalists, research stated, "Immune thrombocytopenic purpura is thought to be characterized by an immune response against the host's own platelets. If the thrombocytopenia is severe, patients are initially treated with high-dose steroids."
The news reporters obtained a quote from the research, "Other more toxic second line treatments are considered if steroids fail. Here, we report the case of two patients in whom conventional treatment was unsuccessful but who responded to hydroxychloroquine and high-dose vitamin D replacement therapy."
According to the news reporters, the research concluded: "To the best of our knowledge, this is the first description of successful treatment for immune thrombocytopenia with high-dose vitamin D and hydroxychloroquine."
For more information on this research see: Refractory immune thrombocytopenia successfully treated with high-dose vitamin D supplementation and hydroxychloroquine: two case reports. Journal of Medical Case Reports, 2013;7(1):91. (BioMed Central - www.biomedcentral.com/; Journal of Medical Case Reports - www.jmedicalcasereports.com)
Our news correspondents report that additional information may be obtained by contacting B. Bockow, Arthritis Northwest, 16122 8th Ave SW, Seattle, WA, 98166, United States (see also Blood Research).
Keywords for this news article include: Seattle, Washington, United States, Blood Research, Thrombocytopenia, Hematologic Diseases, Blood Platelet Disorders, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .